Breast Cancer

Cancer Center of Kansas to Study Novel Cancer Immunotherapy in Advanced Breast Cancer

The Cancer Center of Kansas (CCK) has been added as a new clinical trial site and will be part of an ongoing, multicenter, Phase IIa study of Bria-IMT™ (listed in ClinicalTrials.gov as NCT03066947) in advanced breast cancer, as well as the rollover combination study of  BriaCell Therapeutic’s Bria-IMT™ with pembrolizumab or ipilimumab (listed in ClinicalTrials.gov […]